📷 Image: Wikimedia Commons / Network7research
Health
Pfizer Reaffirms Patient Safety After Karnataka FDA Action
✍️ business-standard.com
🗓 23 Sep 2026, 10:41 AM
👁 18
Pfizer said patient safety remains its top priority following a recent regulatory action by the Karnataka state food and drug authority.
Bengaluru, Karnataka – Pfizer India issued a statement emphasizing that safeguarding patients is its foremost concern after the Karnataka State Food and Drug Administration (FDA) initiated an inspection of the company's local operations. The regulator’s action, reported earlier this week, focused on compliance with manufacturing and distribution standards for several of the company's medicines.
In response, Pfizer highlighted its adherence to global quality protocols and assured that all products in the Indian market meet stringent safety criteria. The company also indicated that it is cooperating fully with the state authority and has taken steps to address any observations raised during the inspection.
The FDA’s review is part of a broader effort by Indian state regulators to tighten oversight of pharmaceutical firms amid growing concerns about drug quality. Pfizer’s reaffirmation aims to reassure healthcare providers and patients that its products remain safe and effective.
No further regulatory penalties have been announced, and the company expects the matter to be resolved promptly, allowing uninterrupted supply of its medicines across the region.
In response, Pfizer highlighted its adherence to global quality protocols and assured that all products in the Indian market meet stringent safety criteria. The company also indicated that it is cooperating fully with the state authority and has taken steps to address any observations raised during the inspection.
The FDA’s review is part of a broader effort by Indian state regulators to tighten oversight of pharmaceutical firms amid growing concerns about drug quality. Pfizer’s reaffirmation aims to reassure healthcare providers and patients that its products remain safe and effective.
No further regulatory penalties have been announced, and the company expects the matter to be resolved promptly, allowing uninterrupted supply of its medicines across the region.